ADVERTISEMENT
COVID shots should target JN.1 variant in 2024-25 campaign, US FDA says
FDA's advisory is in line with European and World Health Organization recommendations
FILE PHOTO: Syringes are pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., May 19, 2022. / REUTERS/Hannah Beier
(Reuters) -The U.S. Food and Drug Administration on June 7 advised COVID-19 vaccine manufacturers that new shots for the fall 2024 campaign should target the JN.1 variant that was dominant earlier this year.
The FDA's advisory is in line with European and World Health Organization recommendations and comes after the U.S. agency's advisers overwhelmingly backed the targeting of the older JN.1 variant over the now-dominant KP.2 strain.
The advisers recommended the older strain, as it is the only strain that Novavax, one of the vaccine makers, said it would be able to target with its shot.
Separately, another vaccine maker Moderna said on Friday it has filed an application with the FDA for its COVID-19 shot targeting the JN.1 strain.
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login